Memorial Sloan-Kettering Cancer Center investigators have shown for the first time the genetic changes that mediate the metastasis (spread) of lung adenocarcinoma to other parts of the body. Adenocarcinoma, the most common type of lung cancer, frequently spreads to the brain and the bones in patients with advanced disease. The research, published in July in Cell, was led by Joan Massagué, Chair of the Sloan-Kettering Institute's Cancer Biology and Genetics Program. [PubMed Abstract]
A groundbreaking study performed at MSKCC reveals why lung cancer quickly spreads to the brain and bones.
In collaboration with Memorial Sloan-Kettering medical oncologist Mark G. Kris and experimental pathologist Marc Ladanyi, among others, Dr. Massagué's laboratory analyzed samples from 107 primary lung tumors, including 65 that were removed from patients in the earliest stage of disease, and determined which genes were expressed in those tumors. The researchers combined their findings with clinical follow-up data regarding which patients later had their disease metastasize and which did not. In those patients who suffered metastasis, their primary tumors showed an unusually high level of activity in a cellular process called the WNT pathway, as the investigators could tell by looking at the expression of the genes that this pathway controls. This high level of WNT pathway activity was the only predictor of which patients would experience metastatic disease.
The WNT pathway is known to play a role in the formation of colorectal cancers as well as in embryonic development. To confirm their findings, the investigators used cell lines created from two different human lung tumors and injected them into mice. Some of the cells quickly spread to the bones and brain, and when the researchers removed and studied those cells, they found that the WNT pathway was active in them. When the WNT pathway was blocked in those aggressive cells, metastases did not form.
“This work begins to shed light on how metastasis occurs in lung cancer, a serious problem that had not received the attention that it deserves until now,” Dr. Massagué said. “I hope that our ability to make progress will encourage others to join in the effort, with the aim of averting the deadly spread of these tumors.”